Clinical Trials Logo

Solitary Fibrous Tumors clinical trials

View clinical trials related to Solitary Fibrous Tumors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03023124 Active, not recruiting - Clinical trials for Solitary Fibrous Tumors

Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

STRADA
Start date: March 4, 2018
Phase: Phase 2
Study type: Interventional

Phase II randomized study for the comparison of trabectedin versus doxorubicin plus dacarbazine in patients with advanced solitary fibrous tumor

NCT ID: NCT01694654 Active, not recruiting - Clinical trials for Solitary Fibrous Tumors of the Pleura

Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura.

Start date: September 2012
Phase: Phase 4
Study type: Observational

1. To determine the incidence, prevalence and long-term outcome of patients with SFTP in the German spoken part of Switzerland. 2. To define the role of immunohistochemical and molecular techniques, such as immunostaining, FISH and mutational analysis regarding their ability to predict malignant behavior in terms of prediction of overall survival and disease-free survival.

NCT ID: NCT01117844 Active, not recruiting - Meningioma Clinical Trials

Proton Radiation For Meningiomas and Hemangiopericytomas

Start date: February 4, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Feasibility/Phase II study for patients with a diagnosis of WHO Grade I - III Meningioma & Hemangiopericytoma brain cancer to be given standard dose Proton radiotherapy. The study will be performed in two phases: first, feasibility with an enrollment of 12 patients and then Phase Page 8 of 20 II, with an enrollment of an additional 38 patients. All patients will also be given quality of life (QOL) instruments pretreatment, weekly during treatment, then q 3 months for year 1 post treatment, q6 months year 2 & 3 and yearly for year 4 & 5. Comparisons will be made between the enrolled subjects receiving proton therapy and the known literature on photon radiation. See section 2 for full objectives. The second phase will begin no earlier than 60 days after the last patient in the initial phase has completed treatment and once safety and feasibility has been verified. The secondary objectives will serve as the objectives for the second phase of the study.